Skip to main content

Brea C. Lipe, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Office: (585) 275-5823

Fax: (585) 273-1051

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



I am the clinical director of Wilmot's multiple myeloma program, and in the laboratory and in the clinic, I am focused on improving the care of patients with multiple myeloma and other plasma cell dyscrasias. Treatment options and our understanding of multiple myeloma have changed dramatically in the last 10 years. The rapid pace of change, intrinsic disease complexity, and the ability to impact patient lives still leaves me amazed and humbled every day.

I believe that it's important to know my patients as individuals to understand the situational circumstance and personality that drives their treatment goals. Multiple myeloma is a lifelong journey and a strong partnership with my patients is essential to achieving the best quality of care. I have a strong interest in clinical research and like to offer my patients a variety of clinical trial options and treatments based on the most recent data. I have a dedicated support team, so that we can offer patients a team with real myeloma-specific expertise.

In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.

Outside of work, I love to grow things -- flowers, vegetables, orchids, animals, children. I have gotten some of my best gardening tips from my patients.

Conditions I treat:

- Multiple myeloma
- Other plasma cell disorders


In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.




    MD | Albany Medical College

    Post-doctoral Training & Residency

    07/01/2008 - 06/30/2011
    Fellowship in Hematology & Oncology at Dartmouth-Hitchcock Medical Center

    07/01/2006 - 06/30/2008
    Residency in Internal Medicine at Dartmouth-Hitchcock Medical Center

    07/01/2005 - 06/30/2006
    Internship in Internal Medicine at Dartmouth-Hitchcock Medical Center

    VIEW ALL expand_more


    2017 - Present
    Leadership Academy
    Sponsor: Southwest Oncology Group (SWOG)

    Department of Internal Medicine OSARM Faculty Incubator Scholar

    Clinical Research Training Institute Clinical Scholar for ASH

    Award for Excellence in Teaching

    Award for Excellence in Teaching

    2001 - 2005
    Frank C. Knievel Scholarship Award

    1996 - 2001
    First Generation Diversity Scholarship

    VIEW ALL expand_more

    Clinical Trials

    Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

    Lead Researcher: Brea C Lipe

    Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.

    View Study Details

    A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

    Lead Researcher: Brea C Lipe

    This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which is given after initial treatment to help keep the cancer from coming back. There are three combinations of four different drugs being studied. Bortezomib is one of the drugs that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide works by helping bone marrow to produce normal blood cells and killing cancer cells. Anti-inflammatory drugs, such as dexamethasone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Patients receive 1 of 3 combinations of these drugs for treatment to determine which combination of study drugs works better to shrink and control multiple myeloma.

    View Study Details

    Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study

    Lead Researcher: Brea C Lipe

    To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.

    View Study Details

    A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

    Lead Researcher: Brea C Lipe

    The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

    View Study Details


    Journal Articles

    Keren DF, Bocsi G, Billman BL, Etzell J, Faix JD, Kumar S, Lipe B, McCudden C, Montgomery R, Murray DL, Rai AJ, Redondo TC, Souter L, Ventura CB, Ansari MQ. "Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology." Archives of pathology & laboratory medicine.. 2021 Aug 4; Epub 2021 Aug 04.

    Lipe, B. "Multiple Myeloma Insights: Older Adults With Multiple Myeloma: Q&A on Care Management" . Medpage Today. 2020; .

    Gasparetto, C; Lentzsch, S; Schiller, G; Callander, N; Tuchman, S; Chen, C; White, D; Kotb, R; Sutherland, H; Sebag, M; Baljevic, M; Bensinger, W; LeBlanc, R; Venner, C; Bahlis, N; Rossi, A; Biran, N; Sheehan, H; Saint-Martin, J; Van Domelen, D; Kai, K; Shah, J; Shacham, S; Kauffman, M; Lipe, B. "Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma" . eJHaem. 2020; .



    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.